Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial.

ABSTRACT: OBJECTIVE:Hybrid closed-loop (HCL) artificial pancreas (AP) systems are now moving from research settings to widespread clinical use. In this study, the inControl algorithm developed by TypeZero Technologies was embedded to a commercial Tandem t:slim X2 insulin pump, now called Control-IQ, paired with a Dexcom G6 continuous glucose monitor and tested for superiority against sensor augmented pump (SAP) therapy. Both groups were physician-monitored throughout the clinical trial. RESEARCH DESIGN AND METHODS:In a randomized controlled trial, 24 school-aged children (6-12 years) with type 1 diabetes (T1D) participated in a 3-day home-use trial at two sites: Stanford University and the Barbara Davis Center (50% girls, 9.6?±?1.9 years of age, 4.5?±?1.9 years of T1D, baseline hemoglobin A1c 7.35%?±?0.68%). Study subjects were randomized 1:1 at each site to either HCL AP therapy with the Control-IQ system or SAP therapy with remote monitoring. RESULTS:The primary outcome, time in target range 70-180?mg/dL, using Control-IQ significantly improved (71.0%?±?6.6% vs. 52.8%?±?13.5%; P?=?0.001) and mean sensor glucose (153.6?±?13.5 vs. 180.2?±?23.1?mg/dL; P?=?0.003) without increasing hypoglycemia time <70?mg/dL (1.7% [1.3%-2.1%] vs. 0.9% [0.3%-2.7%]; not significant). The HCL system was active for 94.4% of the study period. Subjects reported that use of the system was associated with less time thinking about diabetes, decreased worry about blood sugars, and decreased burden in managing diabetes. CONCLUSIONS:The use of the Tandem t:slim X2 with Control-IQ HCL AP system significantly improved time in range and mean glycemic control without increasing hypoglycemia in school-aged children with T1D during remote monitored home use.

SUBMITTER: Forlenza GP 

PROVIDER: S-EPMC6909715 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature